THE LATEST

Read The 2020 Hot Indications List

How can companies determine where to focus as they develop their pipelines and determine new growth opportunities? Kx Advisors’ 2020 Hot Indications List can help. In our 6th annual analysis of global R&D investment, our experts identified the top indications for industry focus.

Download The White Paper

Healthcare Strategy Consulting

Build a winning game
plan for growth

Recognized as a “Top 10 Boutique Consulting Firm” 2023

The Latest

Cell and Gene Therapy: The Next Frontier in Healthcare

Cell and gene therapy is one of the fastest-growing market sectors in health with a strong pipeline and robust deal landscape. Learn why companies are investing in this exciting and innovative therapeutic area.

Read The Paper

Our Focus

Kx Advisors is a different type of healthcare consultancy

Kx Advisors provides growth strategy consulting services to help healthcare executives achieve critical business goals. We live and breathe healthcare growth strategy, and our focus drives results. A highly collaborative approach helps us develop pragmatic solutions for leading pharmaceutical, biotechnology, medical device, health IT, and digital health clients, while our data-driven insights give those clients the tools to compete and win across the healthcare industry.

Learn More

Industry Sectors

Deep sector expertise with a growth strategy focus

“Kx has impressed everyone in our organization. They are really smart people who understand our business and get stuff done.”

- CCO, Pharmaceutical Company

“The Kx team raised the bar for analytical rigor in our organization. They set the standard for what good looks like and we now use them for all our commercial due diligence work.”

- Strategy and Business Development, Medical Device Company

“We don’t need to spend time educating Kx on our business. They just get it and go. Their recommendations are always crystal clear and easy to communicate to our senior executives”

- Strategic Marketing, Pharmaceutical Company

CAPABILITIES

Capabilities that deliver top-line growth

Join Our Team

Make an impact in healthcare

Join Kx colleagues who share a passion for business, science, and solving healthcare’s biggest challenges

Careers

Publications and Recent Insights

Explore our publications and
perspectives

The use of AI in imaging for Alzheimer’s Disease

November 15, 2024 • 2023 has already been a landmark year in Alzheimer’s disease (AD) therapeutics: lecanemab (Leqembi), co-developed by Biogen and Eisai, received FDA accelerated approval in January, and Phase 3 results for donanemab (Eli Lilly) are expected in 2Q23, with submission for FDA full approval shortly thereafter (accelerated approval was rejected in January).

Avatar photoAdriana Gonzalez

OSET 2024: The All-in-One Ortho Industry Meeting

October 7, 2024 • 2023 has already been a landmark year in Alzheimer’s disease (AD) therapeutics: lecanemab (Leqembi), co-developed by Biogen and Eisai, received FDA accelerated approval in January, and Phase 3 results for donanemab (Eli Lilly) are expected in 2Q23, with submission for FDA full approval shortly thereafter (accelerated approval was rejected in January).

Avatar photoMasha Dumanis

Blood Biomarkers in Alzheimer’s Disease

September 25, 2024 • 2023 has already been a landmark year in Alzheimer’s disease (AD) therapeutics: lecanemab (Leqembi), co-developed by Biogen and Eisai, received FDA accelerated approval in January, and Phase 3 results for donanemab (Eli Lilly) are expected in 2Q23, with submission for FDA full approval shortly thereafter (accelerated approval was rejected in January).

Avatar photoJuan Valdez-Capuccino